Phase II Study of Doxorubicin and Avastin® in Sarcoma.
Status:
Terminated
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
This research is being done to find out if adding a drug called Avastin to an already
approved regimen used for soft-tissue sarcoma, Doxorubicin, will improve overall survival,
and slow disease progression. The study will also evaluate the overall safety of combining
these drugs. It is not known if combining these drugs will improve outcome. Avastin has been
approved for the treatment of metastatic carcinoma of the colon or rectum. It is not approved
for the treatment of soft-tissue sarcoma when added to Doxorubicin.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins